FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.
Axsome's AXS-05 gets FDA priority review for treating agitation in Alzheimer's patients, with decision expected by April 2026.
Vanda Pharmaceuticals shares jump 19% in premarket trading after FDA approves Nereus, the first new motion sickness treatment in 40 years.
Big Short investor Michael Burry sees Molina Healthcare as today's Geico, calling it undervalued with strong fundamentals despite 43% stock decline in 2025.
Palisade Bio (PALI) receives Japan patent for PALI-2108, a targeted PDE4 inhibitor for ulcerative colitis and Crohn's disease, with Phase 2 trials planned for 2026.
Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.
